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2360Objective: Since hyperthermia selectively kills lung cancer cells, we developed a venovenous perfusion-
induced systemic hyperthermia system for advanced lung cancer therapy. Our objective was to test the safety
and accuracy of our venovenous perfusion-induced systemic hyperthermia system in 5-day sheep survival
studies, following Good Laboratory Practice standards.
Methods: Our venovenous perfusion-induced systemic hyperthermia system, which included a double-lumen
cannula (Avalon Elite, Rancho Dominguez, Calif), a centrifugal pump (Bio-Pump 560; Medtronic Inc, Minne-
apolis, Minn), a heat exchanger (BIOtherm; Medtronic Perfusion Systems, Brooklyn Park, Minn), and a heater/
cooler (modified Blanketrol IIIl Cincinnati Subzero, Cincinnati, Ohio), was tested in healthy adult sheep (n¼ 5).
The perfusion circuit was primed with prewarmed Plasma-Lyte A (Baxter Healthcare Corp, Deerfield, Ill) and
de-aired. Calibrated temperature probes were placed in the right and left sides of the nasopharynx, bladder, and
blood in/out tubing in the animal. The double-lumen cannula was inserted through the jugular vein into the su-
perior vena cava, with the tip in the inferior vena cava.
Results: Therapeutic core temperature (42C-42.5C), calculated from the right and left sides of the naso-
pharynx and bladder temperatures, was achieved in all sheep. Heating time was 21  5 minutes. Therapeutic
core temperaturewas maintained for 120minutes followed by a cooling phase (35 6minutes) to reach baseline
temperature. All sheep recovered from anesthesia with spontaneous breathing within 4 hours. Arterial, pulmo-
nary, and central venous pressures were stable. Transient increases in heart rate, cardiac output, and blood
glucose occurred during hyperthermia but returned to normal range after venovenous perfusion-induced sys-
temic hyperthermia termination. Electrolytes, complete blood counts, and metabolism enzymes were within
normal to near normal range throughout the study. No significant venovenous perfusion-induced systemic hy-
perthermia–related hemolysis was observed. Neurologic assessment showed normal brain function all 5 days.
Conclusions:Our venovenous perfusion-induced systemic hyperthermia system safely delivered the hyperther-
mia dose with no significant hyperthermia-related complications. (J Thorac Cardiovasc Surg 2014;148:2360-6)Lung cancer is the leading cause of cancer-related deaths in
the United States.1 Non–small cell lung cancer (NSCLC)
accounts for approximately 85% of new lung cancer cases
and is often diagnosed at an advanced stage.2 Patients with
advanced NSCLC have only a 9- to 13.5-month median
survival.3-6 Moreover, chemotherapy results in only a
1.5-month improvement in survival over supportive care
alone.7 Thus, a critical need for more effective lung cancer
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The Journal of Thoracic and Cardiovascular SurHyperthermia is a promising new therapy for advanced
lung cancer because lung cancer cells are thermosensitive
with significantly reduced heat shock protein expression.8
Hyperthermia selectively kills lung cancer cells via
apoptosis8-10 and increases the cytotoxicity of
chemotherapy. Moreover, hyperthermia reverses cisplatin
resistance by enhancing platinum uptake and inhibiting
platinum-induced DNA repair.9-13
Whole-body hyperthermia for advanced cancer treatment
has been proposed since the 1970s.10,14,15 However, it has
not been proven to be clinically practical for cancer
treatment in terms of safety and efficiency. We developed
an efficient yet safe therapeutic hyperthermia dose (42C-
42.5C for 2 hours) for cancer treatment.16-18 Temperatures
below this hyperthermia dose do not kill cancer cells,
whereas temperatures above it will cause normal cell
damage.10,13,19 Precise control of the whole body
temperature to fit this narrow therapeutic hyperthermia
window is difficult. A venovenous perfusion-induced sys-
temic hyperthermia (vv-PISH) systemwas developed to pre-
cisely deliver the thermal dose (42C-42.5C for 2 hours) for
advanced lung cancer treatment. The bulky and complicatedgery c November 2014
Abbreviations and Acronyms
ABP ¼ arterial blood pressure
CPK ¼ creatinine phosphokinase
CVP ¼ central venous pressure
DLC ¼ double-lumen cannula
GLP ¼ Good Laboratory Practice
IV ¼ intravenously
NSCLC ¼ non–small cell lung cancer
PA ¼ pulmonary artery
PAP ¼ pulmonary artery pressure
SC ¼ subcutaneously
vv-PISH ¼ venovenous perfusion-induced systemic
hyperthermia
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worrisome clinical consequences, preventing further clinical
investigation.18 For practical clinical application of hyper-
thermia, we recently developed a simplified vv-PISH system
and management protocol.20,21 We report the results of our
preclinical Good Laboratory Practice (GLP) investigation
that was designed to prove the safety and accuracy of the
simplified vv-PISH system in a 5-day sheep survival study.
Our results showed that an accurate dose of therapeutic
hyperthermia was safely delivered to sheep with no
hyperthermia-related complications.FIGURE1. Hyperthermia temperature profile. A, Bladder, right/left naso-
pharynx temperatures measured during heating, therapeutic, and cooling
phases. Homogeneous heat distribution was observed with no temperatures
greater than 42.5C. B, Relationship between core temperature and circuit
infusion (blood in)/drainage (blood out) temperatures. Maximal circuit
blood infusion temperature was 42.3C.
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All animal studies were approved by the University of Kentucky Insti-
tutional Animal Care and Use Committee, conducted in accordance with
the ‘‘Guide for the Care and Use of Laboratory Animals,’’ and performed
in compliance with GLP standards.22
Anesthesia and Instrumentation
Adult female cross-breed sheep (32-36 kg, n ¼ 5) were intubated after
anesthesia induction with ketamine (5mg/kg, intravenously [IV]) and diaz-
epam (0.25mg/kg, IV), followed by 4% to 5% isoflurane. After intubation,
anesthesia was maintained with 1% to 3% isoflurane through the anes-
thesia machine (Narkomed 2B, DRAGER, Telford, Pa). Prophylactic anal-
gesia (buprenorphine 0.005-0.020 mg/kg, subcutaneously [SC]) and
antibiotic (enrofloxacin 7.5 mg/kg, SC) were administered. The sheep
were ventilated at 8 to 10 mL/kg tidal volumes with 12 to 20 respirations
per minute to maintain 30 to 35 mm Hg end-tidal carbon dioxide.
A Gelli-Roll warming gel pad (Cincinnati Subzero, Cincinnati, Ohio)
was placed under the sheep, and a Warm-Air convective warming blanket
(Cincinnati Subzero) was placed over the sheep before instrumentation.
These external heating devices were set at 38C to maintain baseline
core temperature and set at 42C during the heating and therapeutic phases
to augment hyperthermia. Two 16G catheters (Becton Dickinson, Sandy,
Utah) were placed into the femoral artery and vein for blood sampling/pres-
sure monitoring and fluid administration, respectively. A Swan–Ganz cath-
eter (Edwards Lifesciences, Irvine, Calif) was placed percutaneously
through the left jugular vein to the pulmonary artery (PA) for measurement
of cardiac output, pulmonary artery pressure (PAP), central venous pres-
sure (CVP), and PA blood temperature. The catheters were connected to
transducers (Edwards Lifesciences) for monitoring arterial blood pressure
(ABP), CVP, and PAP via a Phillips MP-50 monitor (Phillips, Boeblingen,The Journal of Thoracic and CarGermany). Temperature probes were placed in the bladder (Foley catheter),
right and left sides of the nasopharynx, and blood in/out tubing. To avoid
isoflurane-induced vasodilation and consequent lower blood pressure
during hyperthermia, the dosage of isoflurane was reduced with the
addition of continuous propofol (0.4 mg/kg/min) IV infusion and bolus
vecuronium IV injection (loading dose: 0.025-0.4 mg/kg, subsequent
doses: 0.007-0.1 mg/kg) to maintain operative anesthesia.
Installation and Maintenance of Venovenous
Perfusion-Induced Systemic Hyperthermia
The vv-PISH system consisted of (1) a double-lumen cannula (DLC)
(Avalon Elite, Rancho Dominguez, Calif)23; (2) a centrifugal pump
(Bio-Pump 560, Medtronic Inc, Minneapolis, Minn); (3) a heat exchanger
(BIOtherm;Medtronic Perfusion Systems, Brooklyn Park,Minn); and (4) a
heater/cooler (modified Blanketrol III; Cincinnati Subzero). The vv-PISH
blood circuit was flushed with carbon dioxide and primed with preheated
(up to 46C) priming solution (Plasma-Lyte A; Baxter Healthcare Corp,
Deerfield, Ill), which circulated with the heater to maintain the
temperature.21
Systemic anticoagulation was initiated with a heparin bolus (150 U/kg,
IV) and maintained at an activated clotting time of 180 to 250 seconds. The
DLC was inserted in the right jugular vein into the superior vena cava,
traversing the right atrium, with the tip positioned in the inferior vena
cava. The DLC was connected to the primed vv-PISH circuit. When the
pump was started, the venous blood was drained from the DLC drainage
lumens (inferior vena cava/superior vena cava) and sent to the heat
exchanger for heating. The heated blood was pumped back through the
DLC infusion lumen into the right atrium–pulmonary circulation. The cir-
cuit blood flowwas 1.5 to 1.6 L/min to heat the sheep, targeting a 42C core
temperature. This 42C core temperature was maintained for 2 hours for
the therapeutic window. After 2 hours of hyperthermia, the cooling phasediovascular Surgery c Volume 148, Number 5 2361
TABLE 1. Hemodynamics
Baseline Heat 39 Heat 40 Heat 41 Therapy start Therapy middle Therapy end Cool 41
MAP 106  11 98  17 108  10 103  9 99  9 102  5 101  5 105  9
HR 110  16 131  14 150  32 152  26* 153  18* 159  27* 156  21* 154  23*
mPAP 14  5 15  4 15  3 15  4 15  4 14  2 16  3 16  2
CVP 3  2.2 4  3.8 4  4.5 4  4.9 4  5.1 5  3.6 6  2.9 6  2.7
CO 4.5  1.7 ND ND ND 8.6  3.3* 10.9  4.3* 10.7  2.7* ND
PAWP 6  3.0 ND ND ND 5  2.5 5  2.3 6  3.1 ND
Hemodynamics were recorded at baseline, heat 39 (core temperature 39C during heating), heat 40 (core temperature 40C during heating), heat 41 (core temperature 41C during
heating), therapy start (when 42C target was met), therapy middle (1 hour at 42C), therapy end (2 hours at 42C), cool 41 (core temperature 41C during cooling), cool 40 (core
temperature 40C during cooling), cool 39 (core temperature 40C during cooling), day 1 (posthyperthermia day 1), day 2 (posthyperthermia day 2), day 3 (posthyperthermia day
3), day 4 (posthyperthermia day 4), and day 5 (posthyperthermia day 5). N ¼ 5 sheep. CO, Cardiac output; CVP, central venous pressure; HR, heart rate; MAP, mean arterial
pressure; mPAP, mean pulmonary artery pressure; ND, not determined; PAWP, pulmonary artery wedge pressure. *P<.05 versus baseline.
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core temperature returned to 39C.
Data Acquisition During Venovenous
Perfusion-Induced Systemic Hyperthermia
The data-acquisition system used in this study was the cDAQ9172
(National Instruments, Austin, Tex) with temperature, pressure, and flow
modules. The temperature module was connected to temperature probes
placed in the bladder, right and left sides of the nasopharynx, and blood
in/out tubing for constant temperature measurement. The core temperature
was defined as the average of the bladder and right and left nasopharynx
temperatures. The pressure module was connected to the pressure sensors
for ABP, CVP, and PAP monitoring. The flow module was connected to a
flow meter (T110, Transonic Systems Inc, Ithaca, NY) for circuit blood
flow monitoring. Data acquisition software (Labview 8.6, National
Instruments) was used to record temperature, blood pressure, and pump
flow rates simultaneously at 5 Hz.
Animal Monitoring and Blood Analysis During
Venovenous Perfusion-Induced Systemic
Hyperthermia
Blood chemistries, complete blood counts, free hemoglobin, cardiac
output, and PAwedge pressure were measured at the following time points:
baseline, therapy start, therapy middle (1 hour of 42C hyperthermia), ther-
apy end (2 hours of 42C hyperthermia), and cool 39 (when 39C was
achieved). Arterial blood gases and electrolytes were measured every 15
minutes using a blood gas analyzer (Cobas b221, Roche Diagnostics, Indi-
anapolis, Ind). Hemodynamics were continuously monitored, and urine
output was measured hourly. Continuous intravenous infusion of lactated
Ringer’s solution (744  205 mL/h) was used to maintain blood volume
for stable hemodynamics. Supplemental calcium chloride (100 mg/mL,
IV) or potassium chloride (10-80 mEq, IV) was used as needed to correct
hypocalcemia or hypokalemia, respectively. A furosemide bolus (10-50
mg, IV) was given if hourly urine output was less than 50 mL.
Five-Day Post–Venovenous Perfusion-Induced
Systemic Hyperthermia Animal Monitoring and
Blood Analysis
After completion of the hyperthermia experiment, the sheep were taken
off perfusion and the DLC was decannulated. The femoral arterial and
Swan–Ganz catheters were left in place throughout the 5-day study for
blood pressure monitoring, blood sampling, and fluid administration. The
sheep were moved into a metabolic cage and transferred to the intensive
care unit. The sheep were weaned from mechanical ventilation/anesthesia.
Once spontaneous breathing maintained normal partial pressure of carbon2362 The Journal of Thoracic and Cardiovascular Surdioxide and partial pressure of oxygen levels, the endotracheal tube was
removed. Thereafter, the sheep had free access to food and
water throughout the study. For the first 2 days, buprenorphine
(0.005-0.02 mg/kg, SC) and enrofloxacin (7.5 mg/kg, SC) were given.
Hemodynamics were continuously monitored and recorded every 6
hours. Blood gases and electrolytes were measured every 6 hours, and
complete blood counts/blood chemistries were measured every 24 hours.
Neurologic assessments were performed every 24 hours. These
assessments were based on the Glasgow Coma scale (0-15), which was
modified for sheep to assess cranial nerve function. A score of 15 on this
modified Glasgow Coma scale was considered normal.
Animal Euthanasia and Necropsy
After successful completion of the 5-day posthyperthermia survival
period, all sheep were euthanized with Beuthanasia-D (1 mL/10 lb body
weight, Schering-Plough, Union, NJ) and subjected to a full necropsy.
The brain, lungs, heart, liver, kidney, gastrointestinal tract, spleen, adrenals,
and bladder were grossly examined, and samples of these tissues
were preserved in 10% buffered formalin. The tissue sections were
paraffin-embedded and stained with hematoxylin–eosin. Slides were exam-
ined by a veterinary histopathology laboratory (Antech Diagnostics,
Louisville, Ky).
Data Analysis
All data are expressed as mean  standard deviation. Differences
between the baseline and subsequent time points were evaluated using
analysis of variance with Dunnett’s post hoc test.RESULTS
All 5 sheep survived the hyperthermia experiment,
achieving 2 hours of 42.0C 0.2C therapeutic hyperther-
mia. All sheep recovered from the vv-PISH procedure, were
awake with spontaneous breathing within 4 hours, and
survived the full 5-day posthyperthermia study period.Venovenous Perfusion-Induced Systemic
Hyperthermia Circuit Efficiency
The baseline core temperature was 38.1C  0.3C.
During the heating phase, a 21  5-minute heating time
was needed to achieve a 42C core temperature. Average
warming rate was 1C per 5.22  0.78 minutes. After the
2 hours of 42C hyperthermia were completed, 35  6gery c November 2014
Cool 40 Cool 39 Day 1 Day 2 Day 3 Day 4 Day 5
104  8 101  13 98  9 90  3 95  5 98  9 93  3
160  24* 161  37* 102  6 103  14 104  9 104  9 112  26
16  2 16  1 14  3 15  3 15  3 14  2 15  3
7  3.1 7  3.1 0  2.6 1  3.7 1  2.7 0  1.0 1  1.2
ND 11.5  2.3* 8.2  0.8 7.4  1.2 7.9  1.1 6.9  1.1 7.2  1.3
ND 5  1.1 7  1.5 7  2.4 7  1.5 7  2.3 9  2.3
TABLE 1. Continued
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cooling rate was 1C per 12.8  1.2 minutes.
Precise Temperature Control of Venovenous
Perfusion-Induced Systemic Hyperthermia
The sheep temperature did not exceed 42.5C at any
measured site throughout the hyperthermia experiment
(Figure 1, A). Moreover, the core temperature (41.8C-
42.2C) varied by only 0.26C  0.1C during the 2-hour
therapeutic hyperthermia phase (Figure 1, B). The circuit
blood infusion temperature reached a maximum of 42.3C
 0.30C during the heating phase and a minimum of
36.9C  0.18C during the cooling phase (Figure 1, B).
Hemodynamics
Mean arterial pressure, CVP, mean PAP, and PA wedge
pressure were stable and in physiologic range throughout
the vv-PISH experiment and 5-day posthyperthermia period
(Table 1). Heart rate and cardiac output were significantly
increased during the hyperthermia experiment, returning
to baseline values by posthyperthermia day 1 and remaining
stable throughout the rest of the study.
Fluid and Electrolyte Balance
During the hyperthermia experiment, lactated Ringer’s
infusion (3070  683 mL) was used to maintain blood vol-
ume for stable hemodynamics. Urine output was 292 101
mL/h during vv-PISH. The average daily urine output dur-
ing the 5 day posthyperthermia study period was 1454 
345 mL (72  13 mL/h). Blood sodium levels were
within normal physiologic range throughout the vv-PISH
and 5-day posthyperthermia monitoring period (Table 2).
Blood potassium levels were in normal range during the
heating and therapeutic phases, but were lower than physi-
ologic range during the cooling phase. Continuous intrave-
nous potassium chloride supplementation was given during
the first 24 hours after vv-PISH, and blood potassium re-
turned to normal levels by 12 hours after vv-PISH. Blood
calcium and chloride were in physiologic range throughoutThe Journal of Thoracic and Carthe hyperthermia experiment. Bicarbonate and pH were sta-
ble during vv-PISH. The pH levels were slightly elevated
from post–vv-PISH day 1 to 5 (Table 2).
Hematology
Free hemoglobin levels were significantly increased after
instrumentation before starting vv-PISH (baseline, Table 3).
Free hemoglobin levels gradually decreased, reaching 7 3
by vv-PISH termination. During the posthyperthermia
period, free hemoglobin levels were 3 mg/dL (Table 3).
Hematocrit, hemoglobin, and red blood cell counts were
unchanged during vv-PISH and within physiologic range
during the posthyperthermia study period (Table 4).
White blood cell counts were stable during vv-PISH
application but were significantly increased 1 and 2 days
after hyperthermia administration, returning to baseline
levels by day 3 (Table 4). The percentages of granulocytes,
lymphocytes, and monocytes were unchanged (data not
shown). Platelet counts were significantly reduced at post-
hyperthermia days 1 to 3 but were still within normal range.
Blood Comprehensive Metabolism
Blood glucose was elevated slightly above physiologic
level during the therapeutic and cooling phases but returned
to baseline values by posthyperthermia day 1 (Table 4).
Throughout the study, alkaline phosphatase levels were sta-
ble. Alanine aminotransferase and aspartate aminotrans-
ferase levels were unchanged during vv-PISH, but they
were significantly elevated on posthyperthermia days 1 to
3, returning to normal range by day 4. Throughout the study,
blood urea nitrogen and creatinine were in the normal range
(Table 4). Albumin and total protein were slightly below the
normal range during the therapeutic and cooling phases, but
returned to baseline values by posthyperthermia day 1.
Creatinine phosphokinase (CPK) levels were not
significantly altered during vv-PISH application (Table 4).
However, CPK levels were elevated 1 and 2 days after
hyperthermia, returning to baseline values by posthyper-
thermia day 3.diovascular Surgery c Volume 148, Number 5 2363
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All 5 sheep scored 15 on the Glasgow Coma scale
throughout the posthyperthermia period, indicating normal
cranial nerve function. The sheep exhibited normal
behavior in terms of eating, standing, and response to
humans.
Histology
No abnormalities were observed in the brain, heart, and
adrenal glands of all 5 sheep. The lungs in all sheep had
areas of atelectasis that were likely due to previous lung
infection or anesthetic procedure. Mild diffuse hepatocellu-
lar cytoplasmic clumping and coagulation were found in the
livers of all 5 sheep, an effect likely due to mild hypoxia.
Two sheep had 1 kidney exhibiting signs of ischemic injury,
whereas the other kidney was normal. The stomach in 3
sheep showed signs of gastritis. Inflammation with coexist-
ing parasitism was present in the intestinal tract of all 5
sheep. Spleen congestion also was found in 4 sheep.
DISCUSSION
In this 5-day GLP-compliant sheep survival study, our
simplified vv-PISH system safely delivered an accurate
therapeutic hyperthermia dose with no evidence of
immediate or long-term hyperthermia-related complica-
tions. With our vv-PISH system, fast heating with stable
ABP/PAP/CVP, normal to near normal levels of blood
electrolytes/metabolic enzymes/hematologic parameters,
and negligible vv-PISH–related hemolysis were achieved
with rapid anesthesia recovery.
The vv-PISH system uses an extracorporeal pump-heat
exchanger circuit to withdraw a portion of venous blood
for heating, which is then pumped back into the pulmo-
nary system where it is well mixed with unheated venous
blood. This heated blood from the pulmonary circulation
is then evenly distributed to the systemic circulation by
the left side of the heart to achieve homogenous heat de-
livery.16,18,21 With the vv-PISH system, hyperthermia
can be delivered to all sites affected by metastatic cancer,
including the visceral organs and previously privileged
areas for cancer metastasis, such as the bone marrow,TABLE 2. Electrolytes
Baseline
Therapy
start
Therapy
middle
Therapy
end Cool 41 Cool 40
Naþ 141  1 139  2 137  2* 136  1* 136  1* 136  2*
Kþ 3.52  0.43 4.01  0.38 3.93  0.42 3.74  0.20 3.33  0.27 3.13  0.17
Ca2þ 1.15  0.07 1.09  0.02 1.11  0.04 1.18  0.14 1.12  0.06 1.09  0.06
Cl 102  2 103  1 100  2 99  1 101  1 101  2
HCO3 27.9  0.7 26.4  1.2 26.9  0.8 27.0  0.5 25.6  0.7 25.1  0.9
pH 7.41  0.07 7.39  0.03 7.40  0.03 7.41  0.03 7.42  0.01 7.41  0.02
Arterial blood electrolytes were measured at baseline, therapy start (when 42C target was
temperature 41C during cooling), cool 40 (core temperature 40C during cooling), cool 39
hyperthermia day 2), day 3 (posthyperthermia day 3), day 4 (posthyperthermia day 4), and
bicarbonate; Kþ, potassium; Naþ, sodium. *P<.05 versus baseline.
2364 The Journal of Thoracic and Cardiovascular Surbrain, vertebral column, and mediastinum.16,18 Another
advantage of the vv-PISH system is the shorter heat
time needed to reach the target temperature, which
enhances cancer cell kill by limiting the recruitment of
thermoprotective mechanisms.8,12,18,21,24 Moreover, rapid
heating expedites apoptosis to more efficiently kill
cancer cells.8,24 Thus, the vv-PISH system has significant
advantages that will likely enhance the efficacy of
hyperthermia.
A first-generation vv-PISH circuit was developed by our
group and tested in 10 patients with advanced NSCLC in a
phase I safety trial with promising results.16-18 A DLC-
based extracorporeal circuit for systemic hyperthermia
also has been developed by an Austrian group.25 Although
these systemic hyperthermia systems functioned adequately
in their respective clinical trials, there were several critical
issues requiring resolution. First, unstable hemodynamics
in all the patients required norepinephrine, large volume
fluid resuscitation (6 L), and vigorous diuresis.18,25
Second, posthyperthermia somnolence existed for up to
48 hours, and extubation was delayed up to 36 hours
because of pulmonary edema.17,18 Third, moderate
hemolysis and thrombocytopenia were observed.17,25
Fourth, the heating phase was too long (>45 minutes),
allowing time for the cancer cells to develop
thermotolerance.17,18,25
To address these issues, we simplified the vv-PISH circuit
and established anesthesia/circuit management protocols to
prevent arterial hypotension and pulmonary hyperten-
sion.20,21 In the current study, this next-generation
vv-PISH circuit successfully delivered an accurate hyper-
thermia dose. Hemodynamics were stable with no need
for vasopressors or large fluid volumes. All sheep quickly
recovered from anesthesia within 4 hours of vv-PISH termi-
nation. Neurologic assessments were normal in all sheep
throughout the posthyperthermia study period, indicating
the absence of brain injury. There was no vv-PISH
circuit-related hemolysis as indicated by free hemoglobin
levels less than 20 during and after vv-PISH use. Free he-
moglobin levels were elevated after instrumentation but
before vv-PISH circuit hook-up, an effect most likely dueCool 39 Day 1 Day 2 Day 3 Day 4 Day 5
135  2* 147  2* 147  1* 145  1* 145  2* 146  2*
3.21  0.30 3.96  0.27 4.04  0.13 3.87  0.2 3.92  0.27 3.95  0.37
1.15  0.08 1.22  0.03 1.25  0.07 1.22  0.10 1.26  0.05 1.26  0.04
100  2 110  3* 104  2 106  5 104  2 105  2
25.9  1.4 21.8  2.0* 27.4  2.1 25.4  4.0 24.5  1.7* 24.3  2.3*
7.41  0.02 7.46  0.04 7.48  0.02* 7.48  0.01* 7.51  0.02* 7.49  0.01*
met), therapy middle (1 hour at 42C), therapy end (2 hours at 42C), cool 41 (core
(core temperature 40C during cooling), day 1 (posthyperthermia day 1), day 2 (post-
day 5 (posthyperthermia day 5). N¼ 5 sheep. Ca2þ, Calcium; Cl, chloride; HCO3,
gery c November 2014
TABLE 3. Free hemoglobin
Sheep Presurgery Baseline Therapy start Therapy middle Therapy end Cool 39 Day 1 Day 2 Day 3 Day 4 Day 5
1 7 17 INT INT INT INT 4 3 3 3 3
2 7 20 10 3 3 11 3 3 3 3 3
3 4 25 13 7 6 4 3 4 3 3 3
4 7 43 20 13 10 7 3 3 3 3 3
5 7 43 18 16 13 7 3 3 3 3 3
Mean 6  1.3 30  13* 15  5 10  6 8  4 7  3 3  0.4 3  0.5 3  0.0 3  0.0 3  0.0
Free hemoglobin levels were measured at presurgery (before surgery day), baseline (after instrumentation but before vv-PISH start), therapy start (when 42C target was met),
therapy middle (1 hour at 42C), therapy end (2 hours at 42C), cool 39 (when 39C baseline temperature was restored), day 1 (posthyperthermia day 1), day 2 (posthyperthermia
day 2), day 3 (posthyperthermia day 3), day 4 (posthyperthermia day 4), and day 5 (posthyperthermia day 5). INT, Interference due to severe lipemia in blood sample. *P<.05
versus presurgery.
Ballard-Croft et al Evolving Technology/Basic Scienceto cannulation-induced hemolysis. In the current study,
thrombocytopenia was not observed. With our vv-PISH cir-
cuit, fast heating while maintaining hemodynamic stability
was possible, resulting in a shorter heating time (21 5 mi-
nutes) to reach the 42C core temperature. This is an impor-
tant finding because hyperthermia induction must be rapid
enough to limit thermotolerance but slow enough to main-
tain patient stability.26
In this 5-day sheep survival study, there were no severe
hyperthermia-related complications, indicating the safety
of our vv-PISH system. Slight elevations in liver enzymes
were detected 1 to 3 days after hyperthermia treatment,
but their return to normal range suggests the absence of sig-
nificant liver injury. Two sheep had an ischemic injury to
one of their kidneys. Given the normal renal performance
during the study, and only 1 kidney being involved, it is un-
likely to be related to the systemic hyperthermia treatment.
Nevertheless, renal and hepatic function will be closely
monitored during future patient hyperthermia treatments.
CPK levels were elevated 5-fold 1 day after hyperthermiaTABLE 4. Hematology and blood chemistry
Parameter Baseline
Therapy
start
Therapy
middle
Therapy
end Coo
Hematocrit (%) 26  1 27  0.4 27  0.7 26  1.1 25 
Hemoglobin (g/dL) 9.1  0.5 8.9  0.5 9.0  0.3 8.7  0.5 8.5 
RBC (3106/mL) 9.8  0.7 9.3  0.6 9.3  0.6 8.9  0.6 8.6 
WBC (3103/mL) 5.5  1.9 7.1  2.2 7.5  2.4 6.6  2.3 6.1 
Platelets (3103/mL) 527  59 571  40 588  8 546  42 496 
Glucose (mg/dL) 75  17 101  4* 111  17* 140  21* 147 
ALP (IU/L) 158  40 168  36 166  36 161  31 157 
ALT (IU/L) 12  4 11  4 11  4 10  3 11 
AST (IU/L) 71  9 63  5 67  5 68  4 71 
BUN (mg/dL) 18  3 17  2 18  3 17  3 17 
Creatine (mg/dL) 0.6  0.1 0.6  0.1 0.6  0.1 0.7  0.1 0.7 
Albumin (g/dL) 2.8  0.2 2.4  0.1* 2.4  0.1* 2.3  0.1* 2.2 
Total protein (g/dL) 5.3  0.5 4.4  0.2* 4.2  0.2* 4.0  0.2* 3.9 
CPK (IU/L) 213  16 266  27 336  29 427  83 572 
Complete blood counts were measured at baseline, therapy start (when 42C target was met
baseline temperature was restored), day 1 (posthyperthermia day 1), day 2 (posthypertherm
(posthyperthermia day 5). N¼ 5 sheep. ALP, Alkaline phosphatase; ALT, alanine aminotran
phosphokinase; RBC, red blood cell; WBC, white blood cell. *P<.05 versus baseline.
The Journal of Thoracic and Caradministration, but returned to normal range by day 3. A
39-fold increase in CPK levels also was observed in the pre-
vious vv-PISH clinical trial, and the clinical study by the
Austrian group also found elevations in this enzyme.17,25
Because the release of CPK from skeletal muscle occurs
during a malignant hyperthermia episode,27,28 the increase
in CPK seems to be a normal physiologic response to
hyperthermia.
CONCLUSIONS
In this preclinical GLP study, our vv-PISH system safely
and reliably delivered the therapeutic hyperthermia dose
with no hyperthermia-related complications. We have
planned the following 3 steps toward clinical application
of vv-PISH: (1) a Food and Drug Administration investiga-
tional device exemption for human trial (in process), (2) an
institutional review board–approved clinical trial to prove
the safety of vv-PISH in humans, and (3) a controlled clin-
ical trial to evaluate the efficacy of vv-PISH in lung cancer
treatment.l 39 Day 1 Day 2 Day 3 Day 4 Day 5
2 30  1* 30  3* 27  2 28  1 26  3
0.7 10.4  0.6* 10.5  1* 9.7  0.8 9.9  0.4 9.4  0.7
0.8 11.2  0.9 11.3  1.4 10.3  1 10.6  0.9 10.0  0.9
2.7 12.0  3.7* 10.3  2.7* 8.4  1.6 7.7  2.1 6.9  1.2
54 335  70* 363  47* 393  67* 481  102 462  97
19* 79  8 82  11 82  5 84  16 89  6
32 162  35 156  54 130  29 118  19 121  26
4 70  33* 61  26* 46  20* 32  15 31  13
7 377  127* 301  72* 205  47* 148  33 142  19
3 7  2* 10  2* 10  2* 11  3* 13  3*
0.1 0.6  0.1 0.6  0.1 0.6  0.1 0.6  0.1 0.6  0.1
0.2* 3.0  0.1 2.9  0.1 2.8  0.2 3.0  0.2 2.9  0.2
0.3* 5.5  0.2 5.5  0.2 5.4  0.1 5.7  0.2 5.5  0.2
184 1118  1056* 458  317 196  80 168  93 153  83
), therapy middle (1 hour at 42C), therapy end (2 hours at 42C), cool 39 (when 39C
ia day 2), day 3 (posthyperthermia day 3), day 4 (posthyperthermia day 4), and day 5
sferase; AST, aspartate aminotransferase; BUN, blood urea nitrogen; CPK, creatinine
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